- Home
- CLM vs BLFS Comparison
CLM vs BLFS Comparison
Compare CLM & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLM | BLFS |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CLM | BLFS |
|---|---|---|
| Price | $6.32 | $36.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.29 |
| AVG Volume (30 Days) | ★ 1.7M | 760.0K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.27 |
| EPS | N/A | ★ 0.94 |
| Revenue | N/A | ★ $96,214,000.00 |
| Revenue This Year | N/A | $19.76 |
| Revenue Next Year | N/A | $17.03 |
| P/E Ratio | ★ N/A | $41.62 |
| Revenue Growth | N/A | ★ 16.97 |
| 52 Week Low | $6.23 | $17.86 |
| 52 Week High | $8.53 | $39.76 |
Technical Indicators
Market Signals| Indicator | CLM | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 64.77 |
| Support Level | $6.23 | $34.38 |
| Resistance Level | $6.77 | N/A |
| Average True Range (ATR) | 0.10 | 0.91 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 36.11 | 78.83 |
Price Performance
Historical ComparisonAbout CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.